Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | EGLN1 | Q9GZT9 | 18/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL643192 | 0.86 | ALDH1A1 (0.46) | ALDH1A1EGLN1 | |
| SCHEMBL3922378 | 0.84 | PARP1 (0.55) | ALDH1A1 | |
| SCHEMBL2143826 | 0.81 | ALDH1A1 (0.60) | ALDH1A1EGLN1 | |
| SCHEMBL27872555 | 0.80 | ALDH1A1 (0.77) | ALDH1A1EGLN1 | |
| SCHEMBL2143832 | 0.80 | EGLN1 (0.60) | ALDH1A1EGLN1 | |
| SCHEMBL244112 | 0.80 | EGLN1 (0.68) | ALDH1A1EGLN1 | |
| SCHEMBL2143852 | 0.80 | ALDH1A1 (0.62) | ALDH1A1EGLN1 | |
| SCHEMBL2143868 | 0.78 | ALDH1A1 (0.57) | ALDH1A1EGLN1BCHE | |
| SCHEMBL2015077 | 0.78 | ALDH1A1 (0.39) | ALDH1A1EGLN1 | |
| SCHEMBL2017011 | 0.78 | TRPM8 (0.41) | ALDH1A1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680108-B2 | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110183985-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-07-28 | — | — | US | disclosed |
| WO-2011075630-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183985-A1 | SUBSTITUTED FUSED ARYL AND HETEROARYL DERIVATIVES AS PI3K INHIBITORS | PIK3R1, PIK3R3, PIK3R2 | ALDH1A1 3722/4885EGLN1 1920/4885BCHE 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.